Nanoparticle Paclitaxel Boosts Tumor Control When Added to Liver-Directed Chemoembolization for Breast Cancer Metastases

When breast cancer spreads to the liver, the prognosis is grim. Median survival for patients with breast cancer liver metastases hovers around 20 months, and even as systemic therapies have transformed outcomes elsewhere in the body, the liver remains a stubborn sanctuary of disease. Now, a team of interventional radiologists and oncologists reports that a familiar chemotherapy drug, delivered in an unfamiliar way, may meaningfully improve local tumor control in these patients. The study, published in CVIR Oncology, suggests that adding nanoparticle albumin-bound paclitaxel, better known as nab-paclitaxel, to conventional transarterial chemoembolization dramatically reduced tumor progression compared with the standard drug cocktail alone.

Transarterial chemoembolization, or TACE, is a catheter-based procedure that exploits a crucial vulnerability of liver tumors: they feed almost exclusively on the hepatic artery. During TACE, an interventional radiologist threads a microcatheter through the femoral artery into the vessels supplying the tumor, injects a concentrated dose of chemotherapy mixed with iodized oil, and then blocks the feeding artery with embolization particles. The technique traps high drug concentrations inside the tumor while cutting off its blood supply and sparing the rest of the body from systemic exposure. TACE has become a mainstay for primary liver cancer and an option for chemotherapy-refractory metastases, but the pharmacologic arsenal used inside the procedure has barely changed in decades, still relying on combinations of antimetabolites, antitumor antibiotics, and platinum compounds.

That stagnation is what motivated the new study. Paclitaxel, a taxane that poisons cancer cells by stabilizing their microtubules, is a cornerstone of breast cancer treatment, improving response rates and survival in both early and metastatic disease. Yet its conventional formulation requires a solvent that triggers hypersensitivity reactions and forms micelles in the bloodstream that interfere with drug delivery. Nab-paclitaxel sidesteps these problems by binding paclitaxel to human albumin nanoparticles, eliminating the solvent entirely. The albumin shell is more than a passive carrier: it exploits the cell’s natural transcytosis machinery, ferrying the drug across the tumor’s endothelial lining and boosting accumulation inside the tumor. In systemic therapy, nab-paclitaxel has outperformed solvent-based paclitaxel in metastatic breast cancer, and the landmark GeparSepto trial found nearly double the pathologic complete response rate in triple-negative patients treated with the nanoparticle formulation.

The researchers, led by Hamidreza Rouientan and Shahram Akhlaghpoor of the Pardis Noor Medical Imaging and Cancer Center in Tehran, reasoned that if nab-paclitaxel works better as an intravenous drug, it might work even better when injected directly into the tumor’s arterial supply. Their retrospective cohort study enrolled 59 patients treated for breast cancer liver metastases between June 2017 and June 2021. Thirty patients received TACE with 100 milligrams of nab-paclitaxel injected through the tumor-feeding microcatheter, immediately followed by the standard emulsion of carboplatin, mitomycin, and idarubicin mixed with iodized oil and gelatin sponge particles. Twenty-nine matched control patients underwent conventional TACE with the standard cocktail alone. All procedures were performed by a single interventional radiologist with 25 years of experience in hepatic interventions, and tumor response was assessed by an independent radiologist blinded to survival data using the RECIST 1.1 criteria.

The results on local tumor control were striking. Disease control, which combines complete response, partial response, and stable disease, was achieved in 93.3 percent of patients in the nab-paclitaxel group, compared with just 62.1 percent of those receiving conventional TACE, a difference that reached statistical significance. Most dramatic of all was the divergence in tumor progression: only 6.7 percent of nab-paclitaxel patients experienced progressive disease, versus 37.9 percent in the conventional group. The objective response rate, encompassing complete and partial responses, was 60 percent with nab-paclitaxel versus 44.8 percent with conventional TACE, and complete responses were more than three times as common in the nanoparticle group, though these latter differences did not reach statistical significance in the small sample. Multivariable analysis confirmed the pattern, showing that nab-paclitaxel significantly reduced the odds of progressive disease relative to stable disease.

Survival, however, told a more nuanced story. At the data cutoff, the overall survival rate for the entire cohort was 45.3 percent, and there were no statistically significant differences between the two treatment groups at the 6-, 12-, 18-, and 24-month marks. When the researchers applied inverse-probability weighting to adjust for confounding factors such as tumor burden, liver function, and hormone receptor status, the nab-paclitaxel group showed a mean survival advantage of 1.18 years, but the difference was not statistically significant. The study did identify one powerful prognostic factor: patients whose disease was confined to the liver had a 24-month survival rate of 60.6 percent, compared with just 30.8 percent for those with extrahepatic metastases, and liver-only disease was associated with roughly half the risk of death.

Safety findings were reassuring. No treatment-related deaths occurred, and adverse events were recorded at nearly identical rates in both groups, 50 percent after nab-paclitaxel TACE and 58.6 percent after conventional TACE. The most common complaints were abdominal pain, nausea, and fatigue, symptoms that typically lasted two to seven days and resolved with supportive care. This stands in contrast to systemic nab-paclitaxel, whose side effects include myelosuppression, alopecia, and sensory neuropathy. The authors argue that intra-arterial delivery is precisely the point: by concentrating the drug where the tumor lives, the approach achieves higher local doses with lower total drug amounts and minimal exposure of healthy tissue, potentially allowing more frequent treatment sessions than systemic chemotherapy would tolerate.

The findings fit into a broader effort to modernize the drug regimens used in liver-directed therapy. Previous studies have tested additions to the TACE cocktail, with mixed results. One German group found that adding gemcitabine to mitomycin modestly reduced progressive disease from 38.2 percent to 33 percent in breast cancer liver metastases. Other trials of gemcitabine-based TACE and doxorubicin-loaded microspheres reported disease control rates ranging from 44 to 83 percent. Against this backdrop, the 93.3 percent disease control rate and the near-elimination of progressive disease in the nab-paclitaxel group stand out, even allowing for the caveats of retrospective comparison. The authors suggest that the drug’s albumin-mediated uptake mechanism may be particularly well suited to the tumor biology that TACE creates, where embolization-induced hypoxia and the enhanced permeability of tumor vessels favor nanoparticle accumulation.

The study’s limitations are real and the authors acknowledge them candidly. The retrospective design, the single-center setting, and the modest sample size of 59 patients all constrain the strength of the conclusions, and the nab-paclitaxel group was treated as part of an evolving multidisciplinary strategy rather than a randomized protocol. Selection bias was mitigated but not eliminated by matching and statistical weighting. Larger prospective randomized trials with extended follow-up will be needed to determine whether the impressive local control translates into a survival benefit, and the authors suggest that precision medicine approaches, incorporating molecular profiling of individual tumors, may eventually identify which patients stand to gain the most from the nanoparticle formulation.

Even with those caveats, the message is provocative. For a patient population whose median survival is measured in months and whose treatment options narrow quickly after chemotherapy failure, a technique that keeps liver tumors in check with a manageable side-effect profile is not a trivial advance. The authors conclude that incorporating nab-paclitaxel into TACE could be a reasonable treatment option for breast cancer liver metastases until proven otherwise, a carefully hedged endorsement that nonetheless signals a shift: after years of relying on the same aging drug cocktails, interventional oncology may finally be ready to update its pharmacopeia, one nanoparticle at a time.

Subject of Research: Nab-paclitaxel added to transarterial chemoembolization for breast cancer liver metastases

Article Title: Nab-paclitaxel in conventional trans arterial chemoembolization for breast cancer liver metastasis: it is time to add new drugs to TACE

Article References: Nab-paclitaxel in conventional trans arterial chemoembolization for breast cancer liver metastasis: it is time to add new drugs to TACE. (n.d.). https://doi.org/10.1007/s44343-025-00006-2

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00006-2

Keywords: breast cancer, liver metastases, transarterial chemoembolization, nab-paclitaxel, interventional radiology, interventional oncology, chemotherapy, drug delivery, RECIST, tumor response, nanoparticles, locoregional therapy